JWH-193 is a drug from the aminoalkylindole and naphthoylindole families which acts as a cannabinoid receptor agonist. It was invented by the pharmaceutical company Sanofi-Winthrop in the early 1990s. JWH-193 has a binding affinity at the CB1 receptor of 6 nM, binding around seven times more tightly than the parent compound JWH-200, though with closer to twice the potency of JWH-200 in activity tests. In the United States, all CB1 receptor agonists of the 3-(1-naphthoyl)indole class such as JWH-193 are Schedule I Controlled Substances.
Property | Value |
---|---|
dbo:abstract |
|
dbo:casNumber |
|
dbo:fdaUniiCode |
|
dbo:pubchem |
|
dbo:thumbnail | |
dbo:wikiPageID |
|
dbo:wikiPageLength |
|
dbo:wikiPageRevisionID |
|
dbo:wikiPageWikiLink |
|
dbp:c |
|
dbp:casNumber |
|
dbp:chemspiderid |
|
dbp:h |
|
dbp:iupacName |
|
dbp:legalCa |
|
dbp:legalDe |
|
dbp:legalUk |
|
dbp:legalUs |
|
dbp:n |
|
dbp:o |
|
dbp:pubchem |
|
dbp:smiles |
|
dbp:stdinchi |
|
dbp:stdinchikey |
|
dbp:unii |
|
dbp:verifiedrevid |
|
dbp:width |
|
dbp:wikiPageUsesTemplate | |
dct:subject | |
gold:hypernym | |
rdf:type | |
rdfs:comment |
|
rdfs:label |
|
owl:sameAs | |
prov:wasDerivedFrom | |
foaf:depiction | |
foaf:isPrimaryTopicOf | |
is dbo:wikiPageDisambiguates of | |
is dbo:wikiPageRedirects of | |
is dbo:wikiPageWikiLink of | |
is foaf:primaryTopic of |